<DOC>
	<DOC>NCT00243763</DOC>
	<brief_summary>The primary objective of this study is to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT), and safety profile of CHIR-258 when administered to subjects with refractory or relapsed multiple myeloma (MM).</brief_summary>
	<brief_title>TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<criteria>Confirmed diagnosis of multiple myeloma Evidence of relapsed or refractory disease Intracranial disease or epidural disease Clinically significant cardiac disease Diabetes mellitus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Refractory Multiple Myeloma or</keyword>
	<keyword>Relapsed Multiple Myeloma</keyword>
</DOC>